Status:
COMPLETED
HEALEY ALS Platform Trial - Regimen C CNM-Au8
Lead Sponsor:
Merit E. Cudkowicz, MD
Collaborating Sponsors:
Clene Nanomedicine
Conditions:
Amyotrophic Lateral Sclerosis
Eligibility:
All Genders
18+ years
Phase:
PHASE2
PHASE3
Brief Summary
The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS. Regimen C will evaluat...
Detailed Description
The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS. This trial is designed ...
Eligibility Criteria
Inclusion
- No additional inclusion criteria beyond the inclusion criteria specified in the Master Protocol (NCT NCT04297683).
Exclusion
- The following exclusion criterion is in addition to the exclusion criteria specified in the Master Protocol (NCT NCT04297683).
- History of allergy to gold, gold salts, or colloidal gold preparations.
Key Trial Info
Start Date :
July 30 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 7 2023
Estimated Enrollment :
161 Patients enrolled
Trial Details
Trial ID
NCT04414345
Start Date
July 30 2020
End Date
March 7 2023
Last Update
July 25 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Healey Center for ALS at Mass General
Boston, Massachusetts, United States, 02114